Combination evidence · O-004
Cagrilintide and combination GLP-1 products
Most current attention concerns a fixed-dose combination. Cagrilintide is a long-acting amylin analogue studied alone and with semaglutide. Combination results cannot validate a separately sold vial.
Cagrilintide has human trial evidence, including phase 3 studies of CagriSema, a fixed-dose combination with semaglutide. As of 7 August 2026, no UK-authorised CagriSema or cagrilintide medicine was identified. Results for the combination do not establish the effect, identity, quantity or quality of an online cagrilintide vial.
Claim-level evidence
The phrase “cagrilintide evidence” can refer to monotherapy, coadministration or a fixed-dose combination. These are not interchangeable.
Weight change with cagrilintide alone
Limited human evidence. A phase 2 trial in adults with overweight or obesity reported dose-related weight reductions over 26 weeks compared with placebo. The study supports further development. It does not establish long-term benefit-risk, UK authorisation or the performance of products sold online.
Weight change with CagriSema
Relevant human evidence. REDEFINE 1 and REDEFINE 2 were phase 3 randomised trials of the fixed-dose cagrilintide and semaglutide combination in adults with overweight or obesity, without and with type 2 diabetes respectively. The findings belong to that combination product and trial programme.
Equivalence of an online cagrilintide vial
No reliable evidence identified. A seller’s molecule name or certificate does not establish the authorised manufacturer, formulation, quantity, sterility, storage or clinical performance of the studied product.
Equivalence of a seller-mixed “CagriSema” blend
No reliable evidence identified. Naming two ingredients does not reproduce the fixed-dose combination used in trials. Each identity, amount, formulation, compatibility, stability and microbiological attribute would need evidence.
Why combination evidence stays with the combination
A combination trial estimates the result of the tested product as a whole. It does not isolate how much of the outcome came from cagrilintide, semaglutide, their interaction or the protocol around treatment. Separate study groups can help with comparison, but they do not turn the combination result into a single-agent claim.
The fixed-dose product also has a defined formulation and manufacturing process. A person cannot recreate its evidence by obtaining two research-labelled vials, even if both labels name the expected molecules.
Read about the molecule it is combined with and the product assurance attached to authorised semaglutide medicine.
Regulatory status on the review date
Novo Nordisk submitted CagriSema for US weight-management review in December 2025 and expected a US decision in the fourth quarter of 2026. Its June 2026 investor material said the EU regulatory pathway for obesity and type 2 diabetes was pending the REDEFINE 3 cardiovascular-outcomes trial.
A regulatory submission is not an approval. It also does not create a UK marketing authorisation. The MHRA product database did not identify an authorised cagrilintide or CagriSema medicine on 7 August 2026.
This status can change. The page should be rechecked when FDA, EMA, MHRA or the sponsor announces a decision, or when REDEFINE 3 reports.
The transfer test for an online product
| Question | Evidence available | Conclusion |
|---|---|---|
| Did the studied combination change body weight? | Phase 3 randomised trial results with defined populations and comparators. | Yes, for the studied CagriSema product and protocol. |
| Did cagrilintide alone show a signal? | Phase 2 monotherapy evidence and comparison groups within later programmes. | Human evidence exists, but the benefit-risk record is less complete. |
| Does an online vial contain cagrilintide? | No product-specific evidence from the trial literature. | Unresolved until suitable testing of a linked sample supports identity. |
| Is the amount accurate? | No quantity evidence from the product name or clinical paper. | Requires a separate validated quantitative assay. |
| Is it sterile and suitable for injection? | No such evidence from identity, purity or molecule trials. | Unresolved. Separate microbiological controls are needed. |
Use the evidence-rating method to keep molecule, product and outcome in the same claim sentence.
Source ledger
Primary sources checked on 7 August 2026.
- Cagrilintide phase 2 monotherapy trial · randomised human evidence over 26 weeks.
- REDEFINE 1 · phase 3 CagriSema evidence in adults without diabetes.
- REDEFINE 2 · phase 3 CagriSema evidence in adults with type 2 diabetes.
- Novo Nordisk CagriSema development update · submission and programme status, 2 February 2026.
- Novo Nordisk Q2 2026 presentation · pending US decision and EU pathway.
- MHRA Products · current UK authorisation search.
Editorial method: We record intervention arms exactly. Combination findings stay with the combination unless a study supports a narrower single-agent statement.
Continue the evidence chain
Questions people ask
Is cagrilintide a GLP-1 medicine?
No. Cagrilintide is a long-acting amylin analogue. It is being developed alone and in CagriSema, a fixed-dose combination with the GLP-1 receptor agonist semaglutide. The combination name does not make cagrilintide itself a GLP-1 agonist.
Is CagriSema approved in the UK?
No UK-authorised CagriSema medicine was identified on 7 August 2026. A US submission was under review, while the sponsor described the EU pathway as pending further cardiovascular-outcomes evidence. Submission and trial completion are not approval.
Do CagriSema trials prove a cagrilintide vial works?
No. The trials studied a defined fixed-dose combination under controlled manufacture and protocol oversight. They do not verify the identity, quantity, sterility, formulation or performance of a separate online vial.
Editorial experience
From our work: how we checked this page
For topical-map item O-004, Cagrilintide and combination GLP-1 products was checked as a distinct editorial task, not treated as a generic peptide page. We reviewed 6 unique external sources and 7 internal destinations in the page, then checked that the opening answer, headings, source descriptions and linked next steps stayed within the same claim boundary. The count records links in the published page and is not a claim that every source carries equal evidential weight.
Eleni Kiromitis checked study design, biomedical evidence, evidence directness and laboratory context. Dr Stavroula Nikitopoulou checked clinical claims, adverse effects, contraindications, red flags and patient-facing safety wording. Each reviewer stayed within the remit published on the governance page. Yianni Kiromitis retained responsibility for source verification, editorial decisions and correction management.
We did not use patient experience, a personal treatment outcome, seller testimony or an assumed product identity to support this page. The publication did not independently test a vial for this review. Where a page refers to a laboratory result, that result applies only to the named sample, method and attribute. We kept uncertainty beside the conclusion, recorded which source supports each material claim, and checked that the visible review date matches the publication record. A new controlled study, regulator update, corrected source, analytical report or credible safety signal can trigger reassessment through the public correction route.